Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-0.83%
$126.97
0% positive prob.
5-Day Prediction
-2.38%
$124.99
0% positive prob.
20-Day Prediction
+3.44%
$132.44
0% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q2 2026 | SELL | -0.83% | -2.38% | +3.44% | 100.0% | Pending |
| Q1 2026 | BUY | +1.21% | +2.17% | +1.34% | 100.0% | +3.01% |
| Q4 2025 | BUY | +1.03% | +2.37% | +0.84% | 99.9% | +1.13% |
SEC 8-K filings with transcript text
Aug 4, 2026 · 100% conf.
1D
-0.83%
$126.97
Act: +0.23%
5D
-2.38%
$124.99
20D
+3.44%
$132.44
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.cf06d217.1785967345.9a9ff9bf
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
Apr 30, 2026 · 100% conf.
1D
+1.21%
$110.34
Act: +2.90%
5D
+2.17%
$111.38
Act: +3.01%
20D
+1.34%
$110.48
Act: +8.58%
2 tm2612241d1_ex99-1.htm
Exhibit 99.1
News Release
Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones
Sales Growth Driven by Continued Strength in Oncology and Animal Health, Plus Increasing Contributions From Launches
-Total Worldwide Sales Were $16.3 Billion (5% Growth; 3% Growth ex-FX)
oKEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.0 Billion (12% Growth; 8% Growth ex-FX); Includes KEYTRUDA QLEX Sales of $128 Million
oWINREVAIR Sales Were $525 Million (88% Growth; 87% Growth ex-FX)
oAnimal Health Sales Were $1.8 Billion (13% Growth; 6% Growth ex-FX)
Loss per Share Was $1.72; Non-GAAP Loss per Share Was $1.28; GAAP and Non-GAAP Loss per Share Include a Charge of $3.62 per Share for the Acquisition of Cidara
-Presented New Data From Cardio-Pulmonary Pipeline at ACC.26, Including Positive Results From Phase 3 CORALreef AddOn Trial
-Received U.S. FDA Approval for IDVYNSO, a Once-Daily, Oral Treatment for Certain Adults With Virologically Suppressed HIV-1
-Achieved Multiple Significant Regulatory and Clinical Milestones Across Oncology Pipeline
-Announced Agreement To Acquire Terns Pharmaceuticals, Inc. and Expand Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia; Transaction Expected To Close in May
-Full-Year 2026 Financial Outlook
oNarrows and Raises the Midpoint of Worldwide Sales Range; Now Expects Sales To Be Between $65.8 Billion and $67.0 Billion
oNarrows and Raises Expected Non-GAAP EPS Range To Be Between $5.04 and $5.16
oOutlook Does Not Reflect Any Impact From Proposed Acquisition of Terns Pharmaceuticals, Inc., Which Is Expected To Close in May and Result in a One-Time Charge of Approximately $5.8 Billion or Approximately $2.35 per Share
N.J., April 30, 2026 – Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2026.
1 Available in some markets as KEYTRUDA SC.
- 2 -
“We are moving with speed to transform our portfolio to one with a diversified set of growth drivers across a broad set of therapeutic areas,” said Robert M. Davis, chairman and chief executive officer. “During the first quarter, we continued to strengthen our pipeline with science-led business development, including our planned acquisition of Terns. We also achieved several important milestones, such as the FDA approval of IDVYNSO – which marks a new chapter in our longstanding commitment to people living with HIV. I am pleased with our progress and excited for what’s ahead, as we enter a particularly robust period of Phase 3 data readouts and deliver on the promise of our pipeline for patients.”
Financial Summary
First Quarter
$ in millions, except EPS amounts 2026 2025 Change Change Ex-
Exchange
Sales $16,286 $15,529 5% 3%
GAAP net (loss) income2 (4,240) 5,079 N/M N/M
Non-GAAP net (loss) income that excludes certain items2,3*
(3,156) 5,611 N/M N/M
(1.72) 2.01 N/M N/M
Non-GAAP EPS that excludes certain items3*
(1.28) 2.22 N/M N/M
*Refer to table on page 7.
N/M - Not meaningful.
For the first quarter of 2026, Generally Accepted Accounting Principles (GAAP) loss / earnings per share (EPS) assuming dilution was a loss per share of $1.72 and non-GAAP loss per share was $1.28. Both the GAAP and non-GAAP loss per share were due to a charge for the acquisition of Cidara Therapeutics, Inc. (Cidara) of $3.62 per share.
Non-GAAP
EPS excludes acquisition- and divestiture-related costs and costs related to restructuring programs, as well as income and losses from investments in equity securities.
2 Net (loss) income attributable to the Company.
3 The Company is providing certain 2026 and 2025 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the Company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to this release.
- 3 -
First-Quarter
Sales Performance
The following table reflects sales of the Company’s top products and significant performance drivers.
First Quarter
$ in millions 2026 2025 Change Change Ex-
Exchange Commentary
Total Sales $16,286 $15,529 5% 3%
Pharmaceutical 14,349 13,638 5
Feb 3, 2026 · 100% conf.
1D
+1.03%
$117.03
Act: +2.13%
5D
+2.37%
$118.59
Act: +1.13%
20D
+0.84%
$116.82
Act: +3.81%
false 0000310158
0000310158
2026-02-03 2026-02-03
0000310158
us-gaap:CommonStockMember
2026-02-03 2026-02-03
0000310158
mrk:Sec1.875NotesDue2026Member
2026-02-03 2026-02-03
0000310158
mrk:Sec3.250NotesDue2032Member
2026-02-03 2026-02-03
0000310158
mrk:Sec2.500NotesDue2034Member
2026-02-03 2026-02-03
0000310158
mrk:Sec1.375NotesDue2036Member
2026-02-03 2026-02-03
0000310158
mrk:Sec3.500NotesDue2037Member
2026-02-03 2026-02-03
0000310158
mrk:Sec3.700NotesDue2044Member
2026-02-03 2026-02-03
0000310158
mrk:Sec3.750NotesDue2054Member
2026-02-03 2026-02-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 3, 2026 (February 3, 2026)
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S. Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
Registrant’s telephone number, including area code (908) 740-4000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
3.250% Notes due 2032
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
3.500% Notes due 2037
New York Stock Exchange
3.700% Notes due 2044
New York Stock Exchange
3.750% Notes due 2054
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on February 3, 2026, regarding earnings for the fourth quarter and year end of 2025, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued February 3, 2026, regarding earnings for the fourth quarter and year end of 2025
Exhibit 99.2 Certain supplemental information not included in the press release
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: February 3, 2026 By:
/s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
Oct 30, 2025
false 0000310158
0000310158
2025-10-30 2025-10-30
0000310158
us-gaap:CommonStockMember
2025-10-30 2025-10-30
0000310158
mrk:Sec1.875NotesDue2026Member
2025-10-30 2025-10-30
0000310158
mrk:Sec3.250NotesDue2032Member
2025-10-30 2025-10-30
0000310158
mrk:Sec2.500NotesDue2034Member
2025-10-30 2025-10-30
0000310158
mrk:Sec1.375NotesDue2036Member
2025-10-30 2025-10-30
0000310158
mrk:Sec3.500NotesDue2037Member
2025-10-30 2025-10-30
0000310158
mrk:Sec3.700NotesDue2044Member
2025-10-30 2025-10-30
0000310158
mrk:Sec3.750NotesDue2054Member
2025-10-30 2025-10-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 30, 2025 (October 30, 2025)
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S. Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
Registrant’s telephone number, including area code (908) 740-4000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
3.250% Notes due 2032
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
3.500% Notes due 2037
New York Stock Exchange
3.700% Notes due 2044
New York Stock Exchange
3.750% Notes due 2054
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on October 30, 2025, regarding earnings for the third quarter of 2025, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued October 30, 2025, regarding earnings for the third quarter of 2025
Exhibit 99.2 Certain supplemental information not included in the press release
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: October 30, 2025 By:
/s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
Jul 29, 2025
false 0000310158
0000310158
2025-07-25 2025-07-25
0000310158
us-gaap:CommonStockMember
2025-07-25 2025-07-25
0000310158
mrk:Sec1.875NotesDue2026Member
2025-07-25 2025-07-25
0000310158
mrk:Sec3.250NotesDue2032Member
2025-07-25 2025-07-25
0000310158
mrk:Sec2.500NotesDue2034Member
2025-07-25 2025-07-25
0000310158
mrk:Sec1.375NotesDue2036Member
2025-07-25 2025-07-25
0000310158
mrk:Sec3.500NotesDue2037Member
2025-07-25 2025-07-25
0000310158
mrk:Sec3.700NotesDue2044Member
2025-07-25 2025-07-25
0000310158
mrk:Sec3.750NotesDue2054Member
2025-07-25 2025-07-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 29, 2025 (July 25, 2025)
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S. Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
Registrant’s telephone number, including area code (732) 594-4000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
3.250% Notes due 2032
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
3.500% Notes due 2037
New York Stock Exchange
3.700% Notes due 2044
New York Stock Exchange
3.750% Notes due 2054
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on July 29, 2025, regarding earnings for the second quarter of 2025, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 2.05. Costs Associated with Exit or Disposal Activities.
On July 25, 2025, the Company approved a new restructuring program (2025 Restructuring Program) designed to position the Company for its next chapter of growth and to successfully advance its pipeline and launch new products across multiple therapeutic areas. As part of this program, the Company expects to eliminate certain positions in sales and administrative organizations, as well as research and development. The Company will, however, continue to hire employees into new roles across all strategic growth areas of the business. In addition, the Company will reduce its global real estate footprint and continue to optimize its manufacturing network, aligning the geography of its global manufacturing footprint to its customers and reflecting changes in the Company’s business.
Most actions contemplated under the 2025 Restructuring Program are expected to be largely completed by the end of 2027, with the exception of certain manufacturing actions, which are expected to be substantially completed by the end of 2029. The cumulative pretax costs to
Apr 24, 2025
false 0000310158
0000310158
2025-04-24 2025-04-24
0000310158
us-gaap:CommonStockMember
2025-04-24 2025-04-24
0000310158
mrk:Sec1.875NotesDue2026Member
2025-04-24 2025-04-24
0000310158
mrk:Sec3.250NotesDue2032Member
2025-04-24 2025-04-24
0000310158
mrk:Sec2.500NotesDue2034Member
2025-04-24 2025-04-24
0000310158
mrk:Sec1.375NotesDue2036Member
2025-04-24 2025-04-24
0000310158
mrk:Sec3.500NotesDue2037Member
2025-04-24 2025-04-24
0000310158
mrk:Sec3.700NotesDue2044Member
2025-04-24 2025-04-24
0000310158
mrk:Sec3.750NotesDue2054Member
2025-04-24 2025-04-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 24, 2025 (April 24, 2025)
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S. Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
Registrant’s telephone number, including area code (732) 594-4000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
3.250% Notes due 2032
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
3.500% Notes due 2037
New York Stock Exchange
3.700% Notes due 2044
New York Stock Exchange
3.750% Notes due 2054
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on April 24, 2025, regarding earnings for the first quarter of 2025, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1Press release issued April 24, 2025, regarding earnings for the first quarter of 2025
Exhibit 99.2Certain supplemental information not included in the press release
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: April 24, 2025 By: /s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
Feb 4, 2025
false 0000310158
0000310158
2025-02-04 2025-02-04
0000310158
us-gaap:CommonStockMember
2025-02-04 2025-02-04
0000310158
mrk:Sec1.875NotesDue2026Member
2025-02-04 2025-02-04
0000310158
mrk:Sec3.250NotesDue2032Member
2025-02-04 2025-02-04
0000310158
mrk:Sec2.500NotesDue2034Member
2025-02-04 2025-02-04
0000310158
mrk:Sec1.375NotesDue2036Member
2025-02-04 2025-02-04
0000310158
mrk:Sec3.500NotesDue2037Member
2025-02-04 2025-02-04
0000310158
mrk:Sec3.700NotesDue2044Member
2025-02-04 2025-02-04
0000310158
mrk:Sec3.750NotesDue2054Member
2025-02-04 2025-02-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 4, 2025 (February 4, 2025)
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S. Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
3.250% Notes due 2032
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
3.500% Notes due 2037
New York Stock Exchange
3.700% Notes due 2044
New York Stock Exchange
3.750% Notes due 2054
New York Stock Exchange
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on February 4, 2025, regarding earnings for the fourth quarter and year end of 2024, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued February 4, 2025, regarding earnings for the fourth quarter and year end of 2024
Exhibit 99.2 Certain supplemental information not included in the press release
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: February 4, 2025 By: /s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
Oct 31, 2024
false 0000310158
0000310158
2024-10-31 2024-10-31
0000310158
us-gaap:CommonStockMember
2024-10-31 2024-10-31
0000310158
mrk:Sec0.500NotesDue2024Member
2024-10-31 2024-10-31
0000310158
mrk:Sec1.875NotesDue2026Member
2024-10-31 2024-10-31
0000310158
mrk:Sec3.250NotesDue2032Member
2024-10-31 2024-10-31
0000310158
mrk:Sec2.500NotesDue2034Member
2024-10-31 2024-10-31
0000310158
mrk:Sec1.375NotesDue2036Member
2024-10-31 2024-10-31
0000310158
mrk:Sec3.500NotesDue2037Member
2024-10-31 2024-10-31
0000310158
mrk:Sec3.700NotesDue2044Member
2024-10-31 2024-10-31
0000310158
mrk:Sec3.750NotesDue2054Member
2024-10-31 2024-10-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 31, 2024 (October 31, 2024)
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S. Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
0.500% Notes due 2024
New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
3.250% Notes due 2032
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
3.500% Notes due 2037
New York Stock Exchange
3.700% Notes due 2044
New York Stock Exchange
3.750% Notes due 2054
New York Stock Exchange
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on October 31, 2024, regarding earnings for the third quarter of 2024, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued October 31, 2024, regarding earnings for the third quarter of 2024
Exhibit 99.2 Certain supplemental information not included in the press release
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: October 31, 2024 By: /s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
Jul 30, 2024
false 0000310158
0000310158
2024-07-30 2024-07-30
0000310158
us-gaap:CommonStockMember
2024-07-30 2024-07-30
0000310158
mrk:Sec0.500NotesDue2024Member
2024-07-30 2024-07-30
0000310158
mrk:Sec1.875NotesDue2026Member
2024-07-30 2024-07-30
0000310158
mrk:Sec3.250NotesDue2032Member
2024-07-30 2024-07-30
0000310158
mrk:Sec2.500NotesDue2034Member
2024-07-30 2024-07-30
0000310158
mrk:Sec1.375NotesDue2036Member
2024-07-30 2024-07-30
0000310158
mrk:Sec3.500NotesDue2037Member
2024-07-30 2024-07-30
0000310158
mrk:Sec3.700NotesDue2044Member
2024-07-30 2024-07-30
0000310158
mrk:Sec3.750NotesDue2054Member
2024-07-30 2024-07-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 30, 2024 (July 30, 2024)
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S. Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
0.500% Notes due 2024
New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
3.250% Notes due 2032
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
3.500% Notes due 2037
New York Stock Exchange
3.700% Notes due 2044
New York Stock Exchange
3.750% Notes due 2054
New York Stock Exchange
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on July 30, 2024, regarding earnings for the second quarter of 2024, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1
Press release issued July 30, 2024, regarding earnings for the second quarter of 2024
Exhibit 99.2 Certain supplemental information not included in the press release
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: July 30, 2024 By: /s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
Apr 25, 2024
false 0000310158
0000310158
2024-04-25 2024-04-25
0000310158
us-gaap:CommonStockMember
2024-04-25 2024-04-25
0000310158
mrk:Sec0.500NotesDue2024Member
2024-04-25 2024-04-25
0000310158
mrk:Sec1.875NotesDue2026Member
2024-04-25 2024-04-25
0000310158
mrk:Sec2.500NotesDue2034Member
2024-04-25 2024-04-25
0000310158
mrk:Sec1.375NotesDue2036Member
2024-04-25 2024-04-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 25, 2024 (April 25, 2024)
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S. Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
0.500% Notes due 2024
New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on April 25, 2024, regarding earnings for the first quarter of 2024, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued April 25, 2024, regarding earnings for the first quarter of 2024
Exhibit 99.2 Certain supplemental information not included in the press release
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: April 25, 2024 By: /s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
Feb 1, 2024
false 0000310158
0000310158
2024-01-29 2024-01-29
0000310158
us-gaap:CommonStockMember
2024-01-29 2024-01-29
0000310158
mrk:Sec0.500NotesDue2024Member
2024-01-29 2024-01-29
0000310158
mrk:Sec1.875NotesDue2026Member
2024-01-29 2024-01-29
0000310158
mrk:Sec2.500NotesDue2034Member
2024-01-29 2024-01-29
0000310158
mrk:Sec1.375NotesDue2036Member
2024-01-29 2024-01-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 1, 2024 (January 29, 2024)
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S. Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
0.500% Notes due 2024
New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on February 1, 2024, regarding earnings for the fourth quarter and year end of 2023, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 2.05. Costs Associated with Exit or Disposal Activities.
On January 29, 2024, the Company approved a new restructuring program (the “2024 Restructuring Program”) intended to continue the optimization of the Company’s Human Health global manufacturing network as the future pipeline shifts to new modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency.
The actions contemplated under the 2024 Restructuring Program are expected to be substantially completed by the end of 2031, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $4.0 billion. Approximately 60% of the $4.0 billion will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested; the remainder of the costs will result in cash outlays primarily relating to facility shutdown costs.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued February 1, 2024, regarding earnings for the fourth quarter and year end of 2023
Exhibit 99.2 Certain supplemental information not included in the press release
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf b
Oct 26, 2023
0000310158 false
0000310158
2023-10-26 2023-10-26
0000310158
us-gaap:CommonStockMember
2023-10-26 2023-10-26
0000310158
mrk:Sec0.500NotesDue2024Member
2023-10-26 2023-10-26
0000310158
mrk:Sec1.875NotesDue2026Member
2023-10-26 2023-10-26
0000310158
mrk:Sec2.500NotesDue2034Member
2023-10-26 2023-10-26
0000310158
mrk:Sec1.375NotesDue2036Member
2023-10-26 2023-10-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 26, 2023
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
0.500% Notes due 2024
New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on October 26, 2023, regarding earnings for the third quarter of 2023, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued October 26, 2023, regarding earnings for the third quarter of 2023
Exhibit 99.2 Certain supplemental information not included in the press release
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: October 26, 2023 By: /s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
Aug 1, 2023
0000310158 false
0000310158
2023-08-01 2023-08-01
0000310158
us-gaap:CommonStockMember
2023-08-01 2023-08-01
0000310158
mrk:Sec0.500NotesDue2024Member
2023-08-01 2023-08-01
0000310158
mrk:Sec1.875NotesDue2026Member
2023-08-01 2023-08-01
0000310158
mrk:Sec2.500NotesDue2034Member
2023-08-01 2023-08-01
0000310158
mrk:Sec1.375NotesDue2036Member
2023-08-01 2023-08-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 1, 2023
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
0.500% Notes due 2024
New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on August 1, 2023, regarding earnings for the second quarter of 2023, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued August 1, 2023, regarding earnings for the second quarter of 2023
Exhibit 99.2 Certain supplemental information not included in the press release
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: August 1, 2023 By: /s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
Apr 27, 2023
0000310158 false
0000310158
2023-04-27 2023-04-27
0000310158
us-gaap:CommonStockMember
2023-04-27 2023-04-27
0000310158
mrk:Sec0.500NotesDue2024Member
2023-04-27 2023-04-27
0000310158
mrk:Sec1.875NotesDue2026Member
2023-04-27 2023-04-27
0000310158
mrk:Sec2.500NotesDue2034Member
2023-04-27 2023-04-27
0000310158
mrk:Sec1.375NotesDue2036Member
2023-04-27 2023-04-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 27, 2023
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
0.500% Notes due 2024
New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on April 27, 2023, regarding earnings for the first quarter of 2023 attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued April 27, 2023, regarding earnings for the first quarter of 2023
Exhibit 99.2 Certain supplemental information not included in the press release
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: April 27, 2023 By: /s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
Feb 2, 2023
0000310158 false
0000310158
2023-02-02 2023-02-02
0000310158
us-gaap:CommonStockMember
2023-02-02 2023-02-02
0000310158
mrk:Sec0.500NotesDue2024Member
2023-02-02 2023-02-02
0000310158
mrk:Sec1.875NotesDue2026Member
2023-02-02 2023-02-02
0000310158
mrk:Sec2.500NotesDue2034Member
2023-02-02 2023-02-02
0000310158
mrk:Sec1.375NotesDue2036Member
2023-02-02 2023-02-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 2, 2023
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
0.500% Notes due 2024
New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on February 2, 2023, regarding earnings for the fourth quarter and year end of 2022, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1Press release issued February 2, 2023, regarding earnings for the fourth quarter and year end of 2022
Exhibit 99.2Certain supplemental information not included in the press release
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: February 2, 2023By:/s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
Oct 27, 2022
0000310158 false
0000310158
2022-10-26 2022-10-26
0000310158
us-gaap:CommonStockMember
2022-10-26 2022-10-26
0000310158
mrk:Sec0.500NotesDue2024Member
2022-10-26 2022-10-26
0000310158
mrk:Sec1.875NotesDue2026Member
2022-10-26 2022-10-26
0000310158
mrk:Sec2.500NotesDue2034Member
2022-10-26 2022-10-26
0000310158
mrk:Sec1.375NotesDue2036Member
2022-10-26 2022-10-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 27, 2022 (October 26, 2022)
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
0.500% Notes due 2024
New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. (“Merck”) on October 27, 2022, regarding earnings for the third quarter of 2022, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangment of Certiain Officers.
(b) Merck announced that Kenneth C. Frazier, the Executive Chairman of Merck’s Board of Directors (the “Board”) will retire from the Board, effective November 30, 2022.
In addition, on October 26, 2022, the Board unanimously elected Robert M. Davis, Merck’s current Chief Executive Officer and President as well as a Director on the Board to serve as Chairman of the Board, effective December 1, 2022.
On October 26, 2022, the Company issued a press release announcing the foregoing. The press release is attached as Exhibit 99.3 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1
Press release issued October 27, 2022, regarding earnings for the third quarter of 2022
Exhibit 99.2
Certain supplemental information not included in the press release
Exhibit 99.3
Press release issued October 26, 2022, regarding the appointment of the Chairman of the Board of Directors
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: October 27, 2022 By: /s/ Kelly
Jul 28, 2022
0000310158 false
0000310158
2022-07-28 2022-07-28
0000310158
us-gaap:CommonStockMember
2022-07-28 2022-07-28
0000310158
mrk:Sec0.500NotesDue2024Member
2022-07-28 2022-07-28
0000310158
mrk:Sec1.875NotesDue2026Member
2022-07-28 2022-07-28
0000310158
mrk:Sec2.500NotesDue2034Member
2022-07-28 2022-07-28
0000310158
mrk:Sec1.375NotesDue2036Member
2022-07-28 2022-07-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 28, 2022
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S Employer Identification No.)
126 East Lincoln Avenue, Rahway, NJ (Address of principal executive offices)
07065 (Zip Code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
0.500% Notes due 2024
New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on July 28, 2022, regarding earnings for the second quarter of 2022, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued July 28, 2022, regarding earnings for the second quarter of 2022
Exhibit 99.2 Certain supplemental information not included in the press release
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: July 28, 2022 By: /s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
Apr 28, 2022
0000310158 false
0000310158
2022-04-28 2022-04-28
0000310158
us-gaap:CommonStockMember
2022-04-28 2022-04-28
0000310158
mrk:Sec0.500NotesDue2024Member
2022-04-28 2022-04-28
0000310158
mrk:Sec1.875NotesDue2026Member
2022-04-28 2022-04-28
0000310158
mrk:Sec2.500NotesDue2034Member
2022-04-28 2022-04-28
0000310158
mrk:Sec1.375NotesDue2036Member
2022-04-28 2022-04-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 28, 2022
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S Employer Identification No.)
2000 Galloping Hill Road, Kenilworth, NJ (Address of principal executive offices)
07033 (Zip Code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock ($0.50 par value) MRK New York Stock Exchange
0.500% Notes due 2024
New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on April 28, 2022, regarding earnings for the first quarter of 2022, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued April 28, 2022, regarding earnings for the first quarter of 2022
Exhibit 99.2 Certain supplemental information not included in the press release
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: April 28, 2022 By: /s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
Apr 21, 2022
0000310158 false
0000310158
2022-04-20 2022-04-20
0000310158
us-gaap:CommonStockMember
2022-04-20 2022-04-20
0000310158
mrk:Sec0.500NotesDue2024Member
2022-04-20 2022-04-20
0000310158
mrk:Sec1.875NotesDue2026Member
2022-04-20 2022-04-20
0000310158
mrk:Sec2.500NotesDue2034Member
2022-04-20 2022-04-20
0000310158
mrk:Sec1.375NotesDue2036Member
2022-04-20 2022-04-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 20, 2022
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S Employer Identification No.)
2000 Galloping Hill Road
KenilworthNew Jersey07033
(Address of principal executive (Zip Code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock($0.50 par value) MRK New York Stock Exchange
0.500% Notes due 2024
New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
Item 2.02 Results of Operations and Financial Condition.
The disclosure set forth in Item 8.01 of this Current Report on Form 8-K is also responsive to Item 2.02 of this Current Report on Form 8-K and is incorporated herein by reference.
Item 8.01 Other Events.
In order to align with views expressed by members of the staff of the U.S. Securities and Exchange Commission (the “Staff”) during a recent consultation between companies in Merck & Co., Inc.’s (“Merck” or the “Company”) pharmaceutical industry peer group and the Staff, the Company is changing the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck’s non-GAAP results excluded expenses for upfront and milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions, to the extent the charges were considered by the Company to be significant to the results of a particular period (as well as any related adjustments recorded in a subsequent period). Beginning in 2022, Merck’s non-GAAP results will no longer exclude charges related to these items. This change will not affect the Company’s non-GAAP results to be reported for the first quarter of 2022, nor does it affect previously reported first quarter 2021 non-GAAP results, as the Company had no significant charges related to those items during such periods. However, the change will affect previously reported non-GAAP results for other periods of 2021 and for 2020 as set forth in the Company’s recast 2021 and 2020 non-GAAP results attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 2021 and 2020 Historical Non-GAAP Financial Information Recast to Reflect Reporting Changes
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: April 20, 2022 By: /s/ Kelly E. W. Grez
Kelly E. W. Grez
Corporate Secretary
Feb 3, 2022
0000310158 false
0000310158
2022-02-03 2022-02-03
0000310158
us-gaap:CommonStockMember
2022-02-03 2022-02-03
0000310158
mrk:Sec0.500NotesDue2024Member
2022-02-03 2022-02-03
0000310158
mrk:Sec1.875NotesDue2026Member
2022-02-03 2022-02-03
0000310158
mrk:Sec2.500NotesDue2034Member
2022-02-03 2022-02-03
0000310158
mrk:Sec1.375NotesDue2036Member
2022-02-03 2022-02-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 3, 2022
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey (State or other jurisdiction of incorporation)
1-6571 (Commission File Number)
22-1918501 (I.R.S Employer Identification No.)
2000 Galloping Hill Road, Kenilworth, NJ (Address of principal executive offices)
07033 (Zip Code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock($0.50 par value) MRK New York Stock Exchange
0.500% Notes due 2024
New York Stock Exchange
1.875% Notes due 2026
New York Stock Exchange
2.500% Notes due 2034
New York Stock Exchange
1.375% Notes due 2036
New York Stock Exchange
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.
Incorporated by reference is a press release issued by Merck & Co., Inc. on February 3, 2022, regarding earnings for the fourth quarter and year end of 2021, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.
This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 Press release issued February 3, 2022, regarding earnings for the fourth quarter and year end of 2021
Exhibit 99.2 Certain supplemental information not included in the press release
Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc.
Date: February 3, 2022 By: /s/ Kelly E. W. Grez
Kelly E. W. Grez
Deputy Corporate Secretary
This page provides Merck & Company Inc. (new) (MRK) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on MRK's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.